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INTRODUCTION
Hepatitis C virus (HCV) infects approximately 1.6% of the world's population [1] , and HCV cirrhosis is the leading indication for liver transplantation (LT) in adults [2] . In recipients with viremia at LT, HCV recurrence is universal [3] and survival is reduced.
Progression of liver disease is accelerated after LT, with chronic hepatitis developing in 50-90% of patients by 12 months and bridging fibrosis/cirrhosis in 20-54% by 5 years after LT [4] . Recurrent HCV is the main cause of graft failure and patient death in HCV-infected recipients [5] , and treatment achieving viral eradication before or after LT would improve patient and graft survival [6] .
High viral load, genotype 1 virus, female gender, older donor age, treated cytomegalovirus (CMV) infection and acute rejection were associated with an increased risk of severe recurrent hepatitis C [6] .
Host immune responses may be crucial in determining the fate of the graft in the context of alloimmunity and immunosuppression. Several studies have correlated the expression of human leukocyte antigen (HLA) variants with spontaneous viral clearance or evolution of liver disease in the non-transplant setting, but only a few
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evaluated the association of HLA with severity of HCV disease after transplant [7, 8] .
Single nucleotide polymorphisms (SNP) upstream of the Interleukin 28B (IL28B) gene encoding interferon lambda-3 (IFN-λ-3), were shown to influence the outcome of HCV infection, and the rs12979860 C/C genotype was found to be protective both in the immunocompetent [9, 10] and in the immunosuppressed host [11] [12] [13] .
However, no study addressed the impact of the combination of these two immunogenetic factors on the outcome of LT in HCV recipients.
Interferon and ribavirin were poorly tolerated in transplant candidates while, even if initiated at an early stage of recurrent hepatitis C post-LT, they achieved sustained virological response (SVR) rates around 30% [6, 14, 15] . The addition of first generation protease inhibitors improved SVR rates to 50-60% [16] , however, side effects and drug-drug interactions make this therapy cumbersome [17] . The recent advent of new direct-acting antiviral agents (DAAs) is revolutionizing anti-HCV therapies towards pan-genotypic, interferon-free regimens [18] . In patients with compensated cirrhosis results are similar to patients without cirrhosis [19] , and the associations sofosbuvir-ledipasvir and sofosbuvir-daclatasvir are available also for Child class B and C patients, although severity of liver disease influences response rates (around 80% compared to 95% for Child A) [20, 21] . Therefore, new management paradigms are emerging in the transplant field: to pursue viral eradication before LT (to improve or stabilize liver function in listed patients and to avoid graft infection) [22] or as early as possible after LT (pre-emptive therapy to prevent inflammation and fibrosis in the transplanted liver), rather than waiting for hepatitis C recurrence before starting treatment. However, unpredictable waiting time, risk of patient death and/or tumor progression on the list, occurrence of delayed
This article is protected by copyright. All rights reserved. graft function after LT or of severe kidney impairment both before and after transplant, and the new dilemmas about using HCV-positive donors are fuelling the debate on the best timing for HCV therapy [23] [24] [25] [26] [27] .
In this study on HCV patients managed in the interferon era, we investigated the effects of the recipient immunogenetic make-up on post-transplant graft survival, aiming to provide new data helpful to define the optimal timing to start novel antivirals in the transplant setting.
MATERIALS AND METHODS

Study population
This retrospective study is based on 1,506 consecutive orthotopic LTs performed at the Turin Liver Transplant Center from January 1999 to December 2009. The time span was chosen to obtain long-term follow-up data before the introduction of new antivirals against the HCV. Excluded from the study were 86 pediatric, 11 livingrelated, 8 dominoes and 125 re-transplants as well as 27 primary transplants for which a recipient DNA sample was not available.
Within the remaining 1,249 adult primary LT recipients, 738 were anti-HCV antibody negative and 511 anti-HCV antibody positive; the latter underwent HCV RNA plasma level and genotype determination as part of their pre-transplant work-up. The donors were similarly studied for HCV in blood collected during the brain death observation period.
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Twenty-one anti-HCV positive but HCV RNA negative recipients and 41 anti-HCV positive patients who received the graft from an anti-HCV positive donor were not considered.
Ultimately, 449 HCV viremic recipients of grafts from HCV-negative brain-dead heartbeating donors, represent the study population (Figure 1) . 
HCV testing
Antibodies to HCV were detected in recipient and donor sera by the Architect assay, Abbott Laboratories, Abbott Park, IL, US.
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HLA typing
Recipient and donor peripheral blood was prospectively collected in ethylenediamine-tetra-acetic acid, and genomic DNA was banked after extraction by 'salting out' method or automatically (Macherey-Nagel GmbH, Düren, Germany). HLA loci A and B were typed by serology, while HLA-DRB1 was typed by serology until 2006
and then by molecular low-resolution with sequence-specific primer technology. A sample of recipients and donors was also typed at high resolution by sequencespecific primer technology to detect HLA-DRB1*11 subtypes.
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IL28B SNP typing
We investigated the IL28B rs12979860 (C>T) polymorphism using the biorepository 
Clinical protocol
Immunosuppression was based on calcineurin inhibitors (mainly cyclosporine), antimetabolites and steroids (tapered to suspension in 6 months). Moderate or severe acute rejection episodes were treated with high-dose methylprednisolone boluses on three consecutive days; monoclonal anti-CD3 antibodies were used in steroid-resistant rejections.
Follow-up liver biopsies were performed as dictated by clinical needs. Recurrent hepatitis C was graded and staged by Ishak score [28] .
Therapy against recurrent HCV infection was based on ribavirin and interferon-α or peginterferon-α given for 12 months or according to tolerance. No patient was treated while on the waiting list. Criteria for HCV treatment after LT were absence of
Accepted Article
contraindications (mainly neutropenia, anemia, thrombocytopenia, renal failure, biliary complication, psychiatric disorders), a minimum 3-months interval from LT and mild to moderate fibrosis (score ≥ 2/6 Ishak) or evidence of fibrosing cholestatic hepatitis.
The variables assessed in the study population are shown in Table 3 .
Study outcome
Graft survival was the sole study outcome; patient survival would have been biased by factors influencing the decision whether to retransplant or not a patient with a failing graft in the setting of recurrent HCV disease. Survival results obtained in the 738 non-HCV recipients were compared with the HCV-infected study population.
Statistical analysis
Allelic, phenotypic and genotypic frequencies were assessed by direct counting.
HLA-A,-B,-DRB1 phenotypic frequencies and all other categorical variables were compared by n x m cells chi-square test and Bonferroni post-hoc correction for multiple comparisons. A p value < 0.05 was otherwise considered statistically significant.
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Results for ordinal variables are expressed as mean ± standard deviation or as median and interquartile range, as appropriate. A two-tailed t-test was adopted to compare differences between normally distributed variables (normality assessed by
Kolmogorov-Smirnov test). Differences between not normally distributed variables
were assessed by the Mann-Whitney U test.
To evaluate the effect of individual categorical variables on graft survival, KaplanMeier analysis was employed and survival curves were compared using the log-rank test. Then, a Cox regression model was used to analyze the one-year graft survival with artificial censoring of all graft losses after one year; short-term hazard ratios (HR), 95% confidence intervals and p values were thus calculated.
To obtain a parsimonious set of pre-transplant predictors of graft survival, recipient and donor variables were selected based on the background knowledge (6), irrespective of their performance at univariate analysis. They were fitted simultaneously into a multivariable Cox proportional hazards regression model and a backward selection method was used. In the backward elimination the results of the Wald test for individual variables were examined and the least significant parameter that did not meet the level for staying in the model (set at p-value = 0.157, corresponding to selection by Akaike's information criterion), was removed.
Finally, we checked for interactions by including variables in the model as well as their cross-product and by testing the statistical significance of the cross-product term.
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RESULTS
Comparison of immunogenetic markers
1.1 HLA frequencies Table 1 shows the statistically significant differences in HLA phenotypic frequencies between the 449 HCV-infected recipients and their HCV-negative donors, the complete pattern of HLA frequencies being depicted in Supplementary Table 2 .
Comparing recipients with donors, HLA-B*13 and HLA-B*16 were significantly less frequent in donors, while HLA-DRB1*11 was significantly less frequent in recipients.
In the latter, the frequencies of the other HLA-DRB1 antigens, especially HLA-DRB1*7, were proportionately increased.
The relative frequencies of the most common HLA-DRB1*11 subtypes (DRB1*11:01, *11:02, *11:03, *11:04) were examined in a sample of HLA-DRB1*11-positive recipients and donors. No differences were found, and they were in line with those of the Italian population (Supplementary Table 3 ).
IL28B SNP frequencies
As shown in Table 2 , C allele and C/C genotype were significantly less frequent in HCV-infected recipients than in their HCV-negative donors, and allelic/genotypic frequencies showed Hardy-Weinberg equilibrium in the donors, but not in the recipients (p=0.0039).
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The frequency of C/C genotype was significantly higher in donors aged 70 years or more (Supplementary Table 4) , and C/C donors were older than non-C/C ones (median age: 63 vs. 58 years, p=0.0286).
Graft survival after LT
The median follow-up for surviving grafts was 10 years (range 4.5 to 15.5).
The ten-year graft survival rate was significantly lower in the 449 HCV than in the 738 non-HCV recipients (p<0.00001). The two survival curves started to diverge few months after LT and the gap widened progressively over time (Supplementary
Figure 1).
Within the HCV patients, the HLA-DRB1*11-positive recipients had a graft survival significantly longer than the HLA-DRB1*11-negative ones, with a difference of 17% at ten years (p=0.0183) (Figure 2 
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This article is protected by copyright. All rights reserved. stage Liver Disease (MELD) score, donor age and donor IL28B genotype, the recipients lacking both HLA-DRB1*11 and IL28B C/C showed: i) significantly higher HCV RNA levels before and 3 months after LT; ii) higher prevalences of genotype 1 virus, HLA-DRB1 donor/recipient full mismatch, IL28B C/C donor to non-C/C
recipient, positive crossmatch, treated acute rejection, and treated CMV infection; iii)
lower SVR rate to interferon therapy.
Comparing causes of graft loss recorded by attending physicians at the time of the event, severe recurrent hepatitis C was more frequent (31.6% vs. 20.3%, p<0.0001) and twofold increased in both the short (< 1 year: 6.1% vs. 2.7%) and long term (> 5 years: 12.3% vs. 6.3%) in HLA-DRB1*11-negative and IL28B non-C/C recipients, while the rates of graft loss due to recurrent hepatocellular carcinoma (HCC) or not primarily attributed to HCV recurrence were not significantly different between the two groups (Supplementary Table 5 ).
Lastly, the relevance of donor features was analyzed in the HCV recipients lacking both HLA-DRB1*11 and IL28B C/C. Regarding donor immunogenetic profile, receiving a graft from an HLA-DRB1*11-positive donor did not exert an appreciable protective effect, while a trend towards a worse graft survival was detected with Table 6 
IL28B C/C donors (Supplementary
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Multivariable analysis
DISCUSSION
In this study on primary transplants performed for HCV cirrhosis in the interferon era, we found that the combination of HLA-DRB1 and IL28B recipient markers identifies a large population of patients at increased risk of liver graft loss from the early posttransplant period.
Both innate and adaptive immunity play a role in HCV infection, leading to virus elimination in 20-30% of the patients during the acute phase [29, 30] . Presentation of viral peptides to CD4 T-cells occurs preferentially in the context of specific HLA-
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class-II antigens and several studies demonstrated a protective role for HLA-DRB1*11 in HCV infection [7, 31] . HLA-DRB1*11 is less prevalent among HCV patients undergoing LT compared with healthy controls, and a fully mismatched donor/recipient pair at the DRB1 locus is associated with an increased severity of recurrent hepatitis C [8] . On the innate arm of the immune response, the IL28B gene product IFN-λ-3 is induced by viral infections and is up-regulated in hepatocytes and peripheral blood mononuclear cells of individuals with HCV infection [32] . IFN-λ-3
enhances cellular immunity and it may be the main inducer of infection suppressor genes following HCV infection [33] . IL28B SNP rs12979860 affects expression of IFN-λ-3, with higher levels of IFN-λ-3 and a higher rate of spontaneous clearance of HCV in patients presenting a C/C genotype [10] . HCV-infected LT recipients with an IL28B genotype different from C/C (i.e. C/T or T/T) have been shown to suffer from earlier HCV recurrence and more severe fibrosis progression; on the contrary, the IL28B C/C genotype in the donor was associated with an adverse outcome in the recipient. Finally, an IL28B C/C genotype both in the recipient and in the donor was found to favor the response to interferon-based therapies [11] [12] [13] .
In our study we confirmed that in HCV recipients HLA-DRB1*11 is uncommon, and the frequency of other HLA-DRB1 alleles is increased; similarly, the frequencies of IL28B C allele and C/C genotype are reduced.
Even if in HCV transplants a full mismatch at the HLA-DRB1 locus was shown to be associated with severity of hepatitis C recurrence [8] , we failed to detect an impact of this donor/recipient combination on graft survival. Conversely, we were able to
extend from fibrosis progression to graft survival the findings of Duarte-Rojo [12] about the detrimental effect of the IL28B mismatch represented by C/C donor to non-C/C recipient.
Focusing on the recipient side, we found a significantly longer survival for HCV patients carrying either HLA-DRB1*11 phenotype or IL28B C/C genotype, independently from the donor's genetic features. More importantly, we identified in half of our HCV recipients an immunogenetic profile (i.e. concurrent absence of both HLA-DRB1*11 and IL28B C/C) which predicted a much worse outcome starting from the first months post-transplant. These 'at risk' subjects did not differ from their 'protected' counterparts for other characteristics which are known to affect LT results such as: recipient age, gender, liver disease severity, hepatocellular carcinoma;
donor age, IL28B genotype, hepatitis B-core antibody positivity; graft macrovesicular steatosis, cold ischemic time; donor age times recipient's MELD (D-MELD) [6, 12, 34] .
On the other hand, they were more often infected with genotype 1 virus, viremia was significantly higher before and three months after LT, and SVR with interferon-based therapies was less frequent, in accordance with the knowledge that the IL28B C/C genotype is a robust predictor of response to interferon [9] and that non-C/C recipients show higher viral loads at hepatitis C recurrence after LT [12] . These data indicate that 'at risk' subjects are less resistant to the HCV both before and after LT.
The immunological risk in these disadvantaged patients was further compounded by the higher prevalence of HLA-DRB1 donor/recipient full mismatch due to the marked phenotypic prevalence of the HLA-DRB1*11 in the general population [8, 35] , the
same selection bias possibly explaining also the higher prevalence of crossmatch positivity. In the 'at risk' recipients, alloimmunity may have increased the occurrence of acute rejection requiring treatment, with consequent weakening of immune defenses and increase of both CMV reactivations and HCV viremic levels 3 months after LT. It is a reasonable inference that this chain of events may favor a more severe course of HCV recurrence, with rapid and progressive injury leading to a higher rate of graft loss starting early after LT.
Though its retrospective nature may be a limit of this study, a high number of patients were consecutively recruited at a single center. They were referred from all parts of Italy, therefore they are representative of an European, mainly Caucasian, population. Secondly, in our Center protocol biopsies are not envisaged, and liver elasticity studies were not available in the initial follow-up years; thus no data are available on the role of HLA-DRB1*11 and IL28B on fibrosis progression [36] . To offset this disadvantage, graft survival from the time of transplant was selected as a more robust outcome than disease evolution.
The recent advent of new highly effective and safe antivirals is providing the mean to eradicate the HCV also in the transplant setting [37] . In the current transition phase in which many HCV candidates are still viremic when accessing to LT waiting lists, pre-transplant DAA-based treatment has been advocated as the most likely to reap most benefits [23] . Other Authors plead, instead, for a more selective use of DAAs in wait-listed patients [25] and suggest to delay HCV therapy after LT in most recipients until their clinical course has stabilized [38] or recurrent hepatitis C has been
This article is protected by copyright. All rights reserved. patients presenting early organ preservation injury, which is more marked in elderly grafts, show the poorest survival outcomes [41] .
In this complex scenario, while waiting for universal hepatitis C eradication before listing, the pre-LT typing of HLA-DRB1 and IL28B helps identifying HCV viremic recipients who are at an increased risk of graft loss starting from the first months after LT. Therefore, our study findings provide a new useful, low-cost decisional element for the timing of DAA-based therapy in the transplant setting, and suggest that immunogenetically 'at risk' patients are high priority candidates for pre-transplant or immediately post-transplant pre-emptive treatment [42, 43] . This indication should be all the more relevant in high MELD candidates and in countries where elderly donors represent an unavoidable resource [44, 45] . Conversely, immunogenetically 'low risk' patients with viremia at LT could undergo antiviral therapy beyond 3 months following LT, when their clinical course has stabilized and early mortality risk has been overcome. 
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